Article
Medicine, General & Internal
Alex R. Schuurman, Tom D. Y. Reijnders, Tjitske S. R. van Engelen, Valentine Leopold, Justin de Brabander, Christine van Linge, Michiel Schinkel, Liza Pereverzeva, Bastiaan W. Haak, Xanthe Brands, Maadrika M. N. P. Kanglie, Inge A. H. van den Berk, Renee A. Douma, Daniel R. Faber, Prabath W. B. Nanayakkara, Jaap Stoker, Jan M. Prins, Brendon P. Scicluna, W. Joost Wiersinga, Tom van der Poll
Summary: This study identifies shared and distinct pathophysiological mechanisms in different aetiologies of community-acquired pneumonia (CAP), which may guide new pathogen-specific therapeutic strategies.
Article
Medicine, General & Internal
August Wrotek, Julita Robakiewicz, Katarzyna Pawlik, Patryk Rudzinski, Izabela Pilarska, Aleksandra Jaron, Aleksandra Imielowska, Malgorzata Jarzebowska, Katarzyna Zablocka, Teresa Jackowska
Summary: Community-acquired pneumonia (CAP) has a significant impact on pediatric hospitalizations. The study analyzed the contribution of CAP to hospitalizations, its etiology in relation to age, and the role of inflammatory markers. It found that CAP accounted for a considerable proportion of hospitalizations and patient days, with viral pneumonia being more common than bacterial pneumonia. Serum inflammatory markers can assist in differentiating the causative factors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Lindsay R. Grant, Elizabeth Begier, Christian Theilacker, Rachid Barry, Cassandra Hall-Murray, Qi Yan, Veneta Pope, Michael W. Pride, Luis Jodar, Bradford D. Gessner
Summary: Nonbacteremic community-acquired pneumonia is a major presentation of severe pneumococcal disease in adults. Urinary antigen detection can guide the use of higher valency pneumococcal conjugate vaccines by detecting the serotypes causing pneumococcal CAP.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Joseph A. Lewnard, Noga Givon-Lavi, Ron Dagan
Summary: The study analyzed the effectiveness of PCV in protecting children against pneumonia caused by different vaccine-targeted pneumococcal serotypes in southern Israel. The results showed that PCV could effectively reduce carriage of vaccine-serotype pneumococci and decrease the risk of disease progression.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Miltiades Kyprianou, Konstantina Dakou, Aftab Aktar, Hichem Aouina, Naser Behbehani, Keertan Dheda, Georges Juvelekian, Adel Khattab, Bassam Mahboub, George Nyale, Sayed Oraby, Abdullah Sayiner, Atef Shibl, Serhat Unal, Mohamed Awad Tag El Deen, Ali Bin Sarwar Zubairi, Ross Davidson, Evangelos J. Giamarellos-Bourboulis
Summary: This meta-analysis demonstrates that the addition of macrolides to the treatment regimen for CAP can significantly reduce 30-day mortality and slightly increase the resolution rate of CAP. The study also found that Streptococcus pneumoniae and Klebsiella pneumoniae are the most common pathogens in under-reported countries.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Luis A. Ruiz, Leyre Serrano, Silvia Perez, Sonia Castro, Amaia Urrutia, Ane Uranga, Amaia Artaraz, Ainhoa Gomez, Pedro P. Espana, Rafael Zalacain
Summary: This study aimed to evaluate the impact of using a predefined cutoff value for lymphopenia as an early predictor of in-hospital mortality and other outcomes in patients with pneumococcal pneumonia. The study found that lymphopenia could be used as a reproducible predictor of complicated clinical course in these patients.
Article
Immunology
David Aguilera-Alonso, Silke Kirchschlager Nieto, Maria Fatima Ara Montojo, Francisco Jose Sanz Santaeufemia, Jesus Saavedra-Lozano, Beatriz Soto, Maria Belen Caminoa, Arantxa Berzosa, Luis Prieto Tato, Emilia Cercenado, Alfredo Tagarro, David Molina Arana, Mercedes Alonso Sanz, Maria Pilar Romero Gomez, Fernando Chaves Sanchez, Fernando Baquero-Artigao
Summary: The incidence of Staphylococcus aureus community-acquired pneumonia (CAP) remained stable in hospitalized children with high pneumococcal vaccination coverage, while the prevalence of pneumococcal CAP decreased and Streptococcus pyogenes CAP increased. Patients with S. aureus CAP had a high frequency of severe outcomes but a lower risk of pulmonary complications compared to patients with S. pneumoniae.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Yuancheng Chen, Xiaojie Wu, Chengyuan Tsai, Liwen Chang, Jicheng Yu, Guoying Cao, Beining Guo, Yaoguo Shi, Demei Zhu, Fupin Hu, Jinyi Yuan, Yang Liu, Xu Zhao, Yingyuan Zhang, Jufang Wu, Jing Zhang
Summary: Integrative PK/PD analysis supports the reliable clinical and microbiological efficacy of nemonoxacin 500 mg q24 h in treating community-acquired pneumonia caused by S. pneumoniae, S. aureus, and K. pneumoniae, regardless of patient sex, mild renal impairment, empty stomach or not. However, nemonoxacin 750 mg q24 h would provide better efficacy than 500 mg q24 h for CAP caused by H. parainfluenzae in terms of CFR.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Microbiology
Andrea Orsi, Alexander Domnich, Stefano Mosca, Matilde Ogliastro, Laura Sticchi, Rosa Prato, Francesca Fortunato, Domenico Martinelli, Fabio Tramuto, Claudio Costantino, Vincenzo Restivo, Vincenzo Baldo, Tatjana Baldovin, Elizabeth Begier, Christian Theilacker, Eva Agostina Montuori, Rohini Beavon, Bradford Gessner, Giancarlo Icardi
Summary: This study aimed to assess the serotype-specific epidemiology of pneumococci among hospitalized older adults in Italy. The prevalence of pneumococcal infection among hospitalized CAP cases was 13.1%, with serotypes 3, 8, 22F, and 11A being the most common. PCV20, which includes these serotypes, plays an important role in preventing pneumonia in older adults.
Article
Immunology
Gina Amanda, Wisnu Tafroji, Dianiati Kusumo Sutoyo, Erlina Burhan, Budi Haryanto, Dodi Safari
Summary: Streptococcus pneumoniae is a major cause of community-acquired pneumonia, with serotype 3 being the most predominant. A significant proportion of isolates show resistance to tetracycline.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2021)
Article
Cardiac & Cardiovascular Systems
Yuto Akiyama, Takashi Ishiguro, Ryuji Uozumi, Takashi Nishida, Yoichi Kobayashi, Noboru Takayanagi
Summary: This study found that age, general condition, comorbidities, and specific pathogens were predictors of long-term prognosis in CAP patients. Respiratory diseases were the most common cause of death post-CAP.
RESPIRATORY MEDICINE
(2021)
Article
Immunology
Yaniv Faingelernt, Ron Dagan, Noga Givon-Lavi, Bart Adriaan van der Beek, Shalom Ben-Shimol, Eilon Shany, David Greenberg
Summary: The implementation of PCV vaccination in Israel has led to a reduction in CAAP incidence in both preterm-born and term-born infants. The reduction rate was higher in outpatients compared to hospitalized children, and the disparity in CAAP rates between preterm-born and term-born infants was also reduced.
Review
Pharmacology & Pharmacy
Arnold Lee, Yvette N. Lamb, Matt Shirley
Summary: Delafloxacin, a fluoroquinolone antibacterial, has demonstrated efficacy in treating community-acquired pneumonia (CAP) and skin infections. It is as effective as moxifloxacin in treating CAP and may be more effective in patients with asthma or COPD. Delafloxacin is well-tolerated and has a low rate of adverse events in CAP patients.
Article
Public, Environmental & Occupational Health
Karin Hansen, Elisabeth Runow, Gustav Torisson, Christian Theilacker, Andreas Palmborg, Kaijie Pan, Qin Jiang, Jo Southern, Rohini Beavon, Bradford D. Gessner, Kristian Riesbeck, Jonas Ahl
Summary: The serotype distribution and potential coverage of pneumococcal conjugate vaccines (PCVs) in adults with community-acquired pneumonia (CAP) in Sweden were unknown. This study found that PCV20 expands the coverage of all-cause CAP compared to PCV13, indicating its potential effectiveness in preventing CAP caused by Streptococcus pneumoniae.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Infectious Diseases
Simon Athlin, Anders Magnuson, Carl Spindler, Jonas Hedlund, Kristoffer Stralin, Pontus Naucler
Summary: This study evaluated the impact of pneumococcal urinary antigen test (UAT) on broad-spectrum antibiotic treatment in patients with community-acquired pneumonia (CAP). The results showed that overall, UAT did not reduce the use of broad-spectrum antibiotics. However, non-severely ill patients with positive UAT results were less likely to receive broad-spectrum antibiotics and antibiotics with coverage for atypical bacteria.
JOURNAL OF INFECTION
(2022)
Review
Infectious Diseases
Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman
Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)
Article
Infectious Diseases
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri
Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)